Redesign of Rifamycin Antibiotics to Overcome ADP‐Ribosylation‐Mediated Resistance
Tian Lan, Uday S. Ganapathy, Sachin Sharma, Yong‐Mo Ahn, Matthew Zimmerman, Vadim Molodtsov, Pooja Hegde, Martin Gengenbacher, Richard H. Ebright, Véronique Dartois, Joel S. Freundlich, Thomas Dick, Courtney C. Aldrich
Abstract
Rifamycin antibiotics are a valuable class of antimicrobials for treating infections by mycobacteria and other persistent bacteria owing to their potent bactericidal activity against replicating and non-replicating pathogens. However, the clinical utility of rifamycins against Mycobacterium abscessus is seriously compromised by a novel resistance mechanism, namely, rifamycin inactivation by ADP-ribosylation. Using a structure-based approach, we rationally redesign rifamycins through strategic modification of the ansa-chain to block ADP-ribosylation while preserving on-target activity. Validated by a combination of biochemical, structural, and microbiological studies, the most potent analogs overcome ADP-ribosylation, restored their intrinsic low nanomolar activity and demonstrated significant in vivo antibacterial efficacy. Further optimization by tuning drug disposition properties afforded a preclinical candidate with remarkable potency and an outstanding pharmacokinetic profile.